Summary of Study ST001136
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000760. The data can be accessed directly via it's Project DOI: 10.21228/M8FH6C This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Study ID | ST001136 |
| Study Title | Metabolme analysis of OPC-163493 on the Liver of ZDF rats (part-II) |
| Study Type | Long-term in vivo test |
| Study Summary | Metabolome analysis were on the 24 samples of ZDF rats that were treated with OPC-163493 for 6-weeks. The 24 samples were composed of 3 different groups (Vehicles, OPC-163493 treatment, and baseline control; each n=8). |
| Institute | Otsuka Pharmaceutical Co., Ltd. |
| Last Name | Kanemoto |
| First Name | Naohide |
| Address | 463-10 Kagasuno Kawauchi-cho Tokushima 771-0192, Japan |
| Kanemoto.Naohide@otsuka.jp | |
| Phone | 81-03-6717-1400 |
| Submit Date | 2019-02-07 |
| Analysis Type Detail | LC-MS |
| Release Date | 2019-03-06 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR000760 |
| Project DOI: | doi: 10.21228/M8FH6C |
| Project Title: | Antidiabetic and cardiovascular beneficial effects of a liver-localized mitochondrial uncoupler |
| Project Summary: | Inducing mitochondrial uncoupling (mUncoupling) is an attractive therapeutic strategy for treating metabolic diseases because it leads to calorie-wasting by reducing the efficiency of oxidative phosphorylation (OXPHOS) in mitochondria. Here we report a safe mUncoupler, OPC-163493, which has unique pharmacokinetic characteristics. OPC-163493 shows a good bioavailability upon oral administration and primarily distributed to specific organs: the liver and kidneys, avoiding systemic toxicities. It exhibitsinsulin-independent antidiabetic effects in multiple animal models of type I and type II diabetes and antisteatotic effects in fatty liver models. These beneficial effects can be explained by the improvement of glucose metabolism and enhancement of energy expenditure by OPC-163493 in the liver. Moreover, OPC-163493 treatment lowered blood pressure, extended survival, and improved renal function in the rat model of stroke/hypertension, possibly by enhancing NO bioavailability in blood vessels and reducing mitochondrial ROS production. OPC-163493 is a liver-localized/targeted mUncoupler that ameliorates various complications of diabetes. |
| Institute: | Otsuka Pharmaceutical Co., Ltd. |
| Last Name: | Kanemoto |
| First Name: | Naohide |
| Address: | 463-10 Kagasuno Kawauchi-cho, Tokushima, Tokusima, 770-0865, Japan |
| Email: | Kanemoto.Naohide@otsuka.jp |
| Phone: | +81-88-665-2126 |
